


Appraisal number	Year of Publication	Process	Technology	Condition	Categorisation	Comment
TA001	2000	MTA	Prophylactic removal	Wisdom teeth	Recommended	Recommendation in line with clinical practice. Moved to static list (review in 2011).
TA002	2000	MTA	Hip prostheses	Hip disease	Recommended	Recommendation in line with clinical practice. Moved to static list.
TA003	2000	MTA	Paclitaxel	Ovarian cancer	Recommended	Guidance has been replaced by TA55. Recommendation in line with marketing authorisation.
TA004	2000	MTA	Coronary artery stents	Ischaemic heart disease	Recommended	Guidance has been replaced by TA71. Recommendation in line with clinical practice.
TA005	2000	MTA	Liquid Based Cytology (LBC)	Cervical cancer	Only in Research	Guidance has been replaced by TA69. At the time of appraisal the Committee advised that there was insufficient evidence to justify the nationwide introduction of LBC technology. However they recommended that large-scale pilot implementation studies should be carried out to evaluate the effectiveness, costs and practical implications of the introduction of LBC technology into the cervical screening programme.
TA006	2000	MTA	Docetaxel	Advanced breast cancer	Recommended	Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
TA006	2000	MTA	Paclitaxel	Advanced breast cancer	Recommended	Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
TA007	2000	MTA	Lansoprazole	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
TA007	2000	MTA	Omeprazole	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
TA007	2000	MTA	Pantoprazole	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.

NICE technology appraisal decisions published since March 2000

1 of 50

 Shaded rows indicate guidance which has been subsequently updated.

TA007	2000	MTA	Rabeprazole	Dyspepsia	Recommended	Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
TA008	2000	MTA	Digital hearing aids	Deafness	Not Recommended	The Department of Health made digital hearing aid technology available across the NHS after TA008 was published which made guidance obsolete. Guidance withdrawn from May 2003.
TA008	2000	MTA	Analogue hearing aids	Deafness	Recommended	The Department of Health made digital hearing aid technology available across the NHS after TA008 was published which made guidance obsolete. Guidance withdrawn from May 2003.
TA009	2000	MTA	Rosiglitazone	Type 2 diabetes	Recommended	Guidance has been replaced by TA63 and incorporated in CG66. Recommendation in line with marketing authorisation.
TA010	2000	MTA	Dry powder inhalers (DPI)	Asthma (under 5 years)	Recommended	Recommendation in line with marketing authorisation.
TA010	2000	MTA	Nebulised therapy	Asthma (under 5 years)	Recommended	Recommendation in line with marketing authorisation
TA010	2000	MTA	Pressurised metered dose inhalers (pMDI) and spacer system	Asthma (under 5 years)	Recommended	Recommendation in line with marketing authorisation
TA011	2000	MTA	Implantable cardioverter defibrillators (ICDs)	Arrhythmias	Recommended	Guidance has been replaced by TA95. Recommendation in line with clinical practice.
TA012	2000	MTA	Abciximab (intravenous)	Acute coronary syndromes	Recommended	Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
TA012	2000	MTA	Eptifibatide (intravenous)	Acute coronary syndromes	Recommended	Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
TA012	2000	MTA	Tirofiban (intravenous)	Acute coronary syndromes	Recommended	Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
TA013	2000	MTA	Methylphenidate	Attention-Deficit Hyperactivity	Recommended	Guidance has been replaced by TA98. Recommendation in line with marketing

				Disorder (ADHD)		authorisation.
TA014	2000	MTA	Interferon alpha	Hepatitis C	Recommended	Guidance has been replaced by TA75 & TA106. Recommendation in line with marketing authorisation.
TA014	2000	MTA	Ribavirin and interferon alpha combination therapy	Hepatitis C	Recommended	Guidance has been replaced by TA75 & TA106. Recommendation in line with marketing authorisation.
TA015	2000	MTA	Zanamivir	Influenza	Recommended	Guidance has been replaced by TA58 and then TA168. Recommendation in line with national influenza guidelines.
TA016	2000	MTA	Autologous Cartilage Transplantation (ACT)	Knee joints (defective)	Only in Research	Guidance has been replaced by TA89. At the time of appraisal it was recommended that ACT should only be performed as part of a properly structured clinical trial, which, wherever possible, is randomised and adequately powered.
TA017	2000	MTA	Laparoscopic surgery	Colorectal cancer	Only in Research	Guidance replaced by TA105. At the time of appraisal it was recommended that laparoscopic surgery for colorectal cancer should be limited to use in a randomised controlled trial setting.
TA018	2001	MTA	Laparoscopic surgery	Hernia	Recommended	Recommendation in line with clinical practice.
TA019	2001	MTA	Donepezil	Alzheimer's disease	Optimised	Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer's disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
TA019	2001	MTA	Galantamine	Alzheimer's disease	Optimised	Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer's disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
TA019	2001	MTA	Rivastigmine	Alzheimer's disease	Optimised	Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances


						in people with Alzheimer's disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
TA020	2001	MTA	Riluzole	Motor neurone disease	Recommended	Recommendation in line with marketing authorisation.
TA021	2001	MTA	Pioglitazone	Diabetes (type 2)	Recommended	Guidance has been replaced by TA63. Recommendation in line with marketing authorisation.
TA022	2001	MTA	Orlistat	Obesity	Recommended	Guidance has been incorporated in CG43. Recommendation in line with marketing authorisation.
TA023	2001	MTA	Temozolomide	Brain cancer (recurrent)	Recommended	Recommendation in line with marketing authorisation.
TA024	2001	MTA	Alginate dressings	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
TA024	2001	MTA	Debriding agents - bio-surgical techniques (sterile maggots)	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
TA024	2001	MTA	Foam dressings	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
TA024	2001	MTA	Hydrocolloids	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
TA024	2001	MTA	Hydrogels	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
TA024	2001	MTA	Polysaccharide beads/paste	Wound care	Recommended	Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
TA025	2001	MTA	Gemcitabine (1st line)	Pancreatic cancer	Recommended	Recommended in line with clinical practice.
TA025	2001	MTA	Gemcitabine (2nd line)	Pancreatic cancer	Not Recommended	At the time of appraisal there was insufficient evidence to support the use of gemcitabine as a second-line treatment in patients with pancreatic adenocarcinoma.

TA026	2001	MTA	Docetaxel (2nd line)	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
TA026	2001	MTA	Gemcitabine (1st line)	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
TA026	2001	MTA	Paclitaxel (1st line)	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
TA026	2001	MTA	Vinorelbine (1st line)	Non-small cell lung cancer	Recommended	Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
TA027	2001	MTA	Celecoxib	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at 'high risk' of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
TA027	2001	MTA	Etodolac	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at 'high risk' of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
TA027	2001	MTA	Meloxicam	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at

						'high risk' of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
TA027	2001	MTA	Rofecoxib	Osteoarthritis and rheumatoid arthritis	Optimised	Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at 'high risk' of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients. Marketing authorisation for this technology was withdrawn by EMA after TA027 was published.
TA028	2001	MTA	Topotecan (2nd and subsequent lines of treatment)	Advanced ovarian cancer	Recommended	Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
TA029	2001	MTA	Fludarabine - Intravenous formulation (2nd line)	Leukaemia (B-cell chronic lymphocytic)	Recommended	Recommendation in line with marketing authorisation.
TA029	2001	MTA	Fludarabine - Oral formulation (2nd line)	Leukaemia (B-cell chronic lymphocytic)	Recommended	Recommendation in line with marketing authorisation.
TA030	2001	MTA	Docetaxel in combination with an anthracycline (1st line)	Advanced breast cancer	Not Recommended	Update of guidance TA6. Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA030	2001	MTA	Docetaxel (2nd line)	Advanced breast cancer	Recommended	Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line

NICE technology appraisal decisions published since March 2000

6 of 50

 Shaded rows indicate guidance which has been subsequently updated.

						with marketing authorisation.
TA030	2001	MTA	Paclitaxel (2nd line)	Advanced breast cancer	Recommended	Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
TA031	2001	MTA	Sibutramine	Obesity	Recommended	Guidance has been incorporated in CG43. Recommendation in line with marketing authorisation.
TA032	2002	MTA	Beta interferon	Multiple sclerosis	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Moved to static list.
TA032	2002	MTA	Glatiramer acetate	Multiple sclerosis	Not Recommended	At the time of appraisal, the technology was not considered to be a good use of NHS resources based on the data available. Moved to static list.
TA033	2002	MTA	Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (1 st -line)	Colorectal cancer (advanced)	Optimised	Guidance has been replaced by TA93. Optimised recommendation for use in specific circumstances in patients with advanced colorectal cancer in patients with metastases that are confined solely to the liver and may become resectable ('down staged') following treatment.
TA033	2002	MTA	Irinotecan in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line)	Colorectal cancer (advanced)	Not Recommended	Guidance replaced by TA93. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA033	2002	MTA	Irinotecan monotherapy (2nd line)	Colorectal cancer (advanced)	Recommended	Guidance replaced by TA93. Recommendation in line with marketing authorisation.
TA033	2002	MTA	Raltitrexed	Colorectal cancer (advanced)	Only in Research	Guidance replaced by TA93. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the

						technology was only recommended for use in the context of appropriately designed clinical trials.
TA034	2002	MTA	Trastuzumab in combination with paclitaxel	Breast cancer	Recommended	Recommendation in line with marketing authorisation.
TA034	2002	MTA	Trastuzumab monotherapy	Breast cancer	Recommended	Recommendation in line with marketing authorisation.
TA035	2002	MTA	Etanercept	Arthritis (juvenile idiopathic)	Recommended	Recommendation in line with marketing authorisation.
TA036	2002	MTA	Etanercept	Rheumatoid arthritis	Optimised	Guidance has been partially replaced by TA130 and TA195. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated).
TA036	2002	MTA	Infliximab in combination with methotrexate	Rheumatoid arthritis	Optimised	Guidance has been replaced by TA130. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated).
TA037	2002	MTA	Rituximab (last line)	Lymphoma (follicular non-Hodgkin's)	Only in Research	Guidance replaced by TA137. At the time of appraisal, the technology was only recommended for last-line therapy in the context of the construction of a case series of past and new patients, to determine with more certainty its effectiveness in this indication.
TA037	2002	MTA	Rituximab (3rd and subsequent lines of treatment)	Lymphoma (follicular non-Hodgkin's)	Not recommended	Guidance replaced by TA137. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA038	2002	MTA	Pressurised metered dose inhalers (pMDIs)	Asthma (older children)	Recommended	Recommendation in line with marketing authorisations.
TA038	2002	MTA	Breath actuated pressurised metered dose aerosol inhalers	Asthma (older children)	Recommended	Recommendation in line with marketing authorisations.

TA038	2002	MTA	Dry powder inhalers (DPI)	Asthma (older children)	Recommended	Recommendation in line with marketing authorisations.
TA039	2002	MTA	Nicotine replacement therapy (NRT) and bupropion in combination	Smoking cessation	Recommended	Guidance has been incorporated in PH10. Recommendation in line with marketing authorisations.
TA039	2002	MTA	Bupropion	Smoking cessation	Recommended	Guidance has been incorporated in PH10. Recommendation in line with marketing authorisation.
TA039	2002	MTA	Nicotine replacement therapy (NRT)	Smoking cessation	Recommended	Guidance has been incorporated in PH10. Recommendation in line with marketing authorisations.
TA040	2002	MTA	Infliximab	Crohn's disease (active severe)	Recommended	Recommendation in line with marketing authorisation.
TA040	2002	MTA	Infliximab	Crohn's disease (fistulising)	Recommended	Recommendation in line with marketing authorisation.
TA041	2002	MTA	Routine antenatal anti-D prophylaxis (RAADP)	Pregnancy	Recommended	Guidance has been replaced by TA156. Recommendation in line with marketing authorisation and clinical practice.
TA042	2002	MTA	Somatropin	Growth hormone deficiency (children)	Recommended	Guidance has been replaced by TA188. Recommendation in line with marketing authorisation.
TA043	2002	MTA	Amisulpride	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
TA043	2002	MTA	Olanzapine	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
TA043	2002	MTA	Quetiapine	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
TA043	2002	MTA	Risperidone	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.

TA043	2002	MTA	Sertindole	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
TA043	2002	MTA	Zotepine	Schizophrenia	Recommended	Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
TA044	2002	MTA	Metal on metal (MoM) hip resurfacing arthroplasty	Hip disease	Only in Research	At the time of appraisal, it was recommended that where hip resurfacing arthroplasty is considered appropriate, the procedure should only be performed in the context of the ongoing collection of data on both the clinical effectiveness and cost-effectiveness of this technology. Ideally this data collection should form part of a UK national joint registry.
TA045	2002	MTA	Pegylated liposomal doxorubicin hydrochloride (PLDH)	Ovarian cancer (advanced)	Recommended	Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
TA046	2002	MTA	Malabsorptive Surgery	Obesity (morbid)	Recommended	Guidance has been incorporated in CG43. Recommendation in line with clinical practice.
TA046	2002	MTA	Restrictive Surgery	Recommended	Recommended	Guidance has been incorporated in CG43. Recommendation in line with clinical practice.
TA047	2002	MTA	Abciximab	Acute coronary syndromes	Recommended	Update of guidance TA12. Recommendation in line with marketing authorisation.
TA047	2002	MTA	Eptifibatide	Acute coronary syndromes	Recommended	Update of guidance TA12. Recommendation in line with marketing authorisation.
TA047	2002	MTA	Tirofiban	Acute coronary syndromes	Recommended	Update of guidance TA12. Recommendation in line with marketing authorisation.
TA048	2002	MTA	Home haemodialysis	Renal failure	Recommended	Recommendation in line with clinical practice.
TA049	2002	MTA	Audio-guided Doppler ultrasound guidance	Central venous catheters	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.

TA049	2002	MTA	Two-dimensional (2-D) imaging ultrasound guidance	Central venous catheters	Optimised	Optimised recommendation for use in specific circumstances for adults and children in elective or emergency situations.
TA050	2002	MTA	Imatinib	Leukaemia (CML)	Recommended	Guidance has been replaced by TA70. Recommendation in line with marketing authorisation.
TA051	2002	MTA	Beating the Blues - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. The evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within 'stepped care' approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
TA051	2002	MTA	Calipso Overcoming Depression Self-Help Materials - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient basis to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within 'stepped care' approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.

TA051	2002	MTA	COPE - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within 'stepped care' approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
TA051	2002	MTA	FearFighter - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within 'stepped care' approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
TA051	2002	MTA	Restoring the Balance - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to

						recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within 'stepped care' approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
TA051	2002	MTA	StressPac - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within 'stepped care' approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects.
TA052	2002	MTA	Alteplase	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
TA052	2002	MTA	Retepase	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
TA052	2002	MTA	Streptokinase	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
TA052	2002	MTA	Tenecteplase	Myocardial infarction	Recommended	Recommendation in line with clinical practice.
TA053	2002	MTA	Insulin glargine	Diabetes (type 1)	Recommended	Recommendation in line with clinical practice.
TA053	2002	MTA	Insulin glargine	Diabetes (type 2)	Optimised	Optimised recommendation for use in specific circumstances for people who require assistance with their treatment administration, or whose

						lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic episodes, or for those who would otherwise need twice daily basal insulin injections in combination with oral anti-diabetic drugs.
TA054	2002	MTA	Vinorelbine monotherapy	Breast cancer	Recommended	Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
TA054	2002	MTA	Vinorelbine combination therapies	Breast cancer	Not Recommended	Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA055	2003	MTA	Paclitaxel (2nd line)	Ovarian cancer	Recommended	Update of guidance TA3. Recommendation in line with marketing authorisation.
TA055	2003	MTA	Paclitaxel (1st line)	Ovarian cancer	Recommended	Update of guidance TA3. Recommendation in line with marketing authorisation.
TA056	2003	MTA	Tension-free vaginal tape (Gynecare TVT)	Stress incontinence	Recommended	Guidance has been incorporated in CG40. Recommendation in line with clinical practice.
TA057	2003	MTA	Continuous subcutaneous insulin infusion (CSII or 'insulin pump therapy')	Diabetes (type 1)	Optimised	Guidance has been replaced by TA151. Optimised recommended for use in specific circumstances, for people whose HbA1c levels have remained high (at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care.
TA057	2003	MTA	Continuous subcutaneous insulin infusion (CSII or 'insulin pump therapy')	Diabetes (type 2)	Not Recommended	Guidance has been replaced by TA151. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA058	2003	MTA	Oseltamivir	Influenza (treatment)	Recommended	Update of guidance TA15. Guidance has been replaced by TA168. Recommendation in line with national influenza guidelines.
TA058	2003	MTA	Amantadine	Influenza (treatment)	Not Recommended	Guidance has been replaced by TA168. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on

						the data available.
TA058	2003	MTA	Zanamivir	Influenza (treatment)	Recommended	Update of guidance TA15. Guidance has been replaced by TA168. Recommendation in line with national influenza guidelines.
TA059	2003	MTA	Electroconvulsive therapy (ECT)	Electroconvulsive therapy (ECT)	Optimised	Optimised recommendation for use in specific circumstances as a last-line treatment option for those with severe depressive illness, catatonia and prolonged or severe manic episode.
TA060	2003	MTA	Structured patient education	Diabetes (type 1 and 2)	Recommended	Recommendation in line with clinical practice.
TA061	2003	MTA	Capecitabine	Colorectal cancer	Recommended	Recommendation in line with marketing authorisation.
TA061	2003	MTA	Tegafur with uracil	Colorectal cancer	Recommended	Recommendation in line with marketing authorisation.
TA062	2003	MTA	Capecitabine	Breast cancer (locally advanced or metastatic)	Recommended	Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
TA062	2003	MTA	Capecitabine, plus docetaxel	Breast cancer (locally advanced or metastatic)	Recommended	Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
TA063	2003	MTA	Pioglitazone in combination with a sulphonylurea	Diabetes (type 2)	Optimised	Update of guidance TA21. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances, for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.

TA063	2003	MTA	Pioglitazone in combination with metformin	Diabetes (type 2)	Optimised	Update of guidance TA21. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
TA063	2003	MTA	Rosiglitazone in combination with a sulphonylurea	Diabetes (type 2)	Optimised	Update of guidance TA9. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
TA063	2003	MTA	Rosiglitazone in combination with metformin	Diabetes (type 2)	Optimised	Update of guidance TA9. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated.
TA064	2003	MTA	Somatropin	Growth hormone deficiency (adults)	Optimised	Optimised recommendation for use in specific circumstances for people who have severe GH deficiency and they have a perceived impairment of quality of life (QoL), as demonstrated by a reported score of at least 11 in the disease-specific 'Quality of life assessment of growth hormone deficiency in adults' (QoL-AGHDA) questionnaire; and they are already receiving treatment for any other pituitary

						hormone deficiencies as required.
TA065	2003	MTA	Rituximab	Non-Hodgkin's lymphoma - stage II - IV	Recommended	Recommendation in line with marketing authorisation.
TA065	2003	MTA	Rituximab	Non-Hodgkin's lymphoma - stage I	Only in Research	At the time of appraisal, the clinical and cost-effectiveness of rituximab in patients with localised (stage 1) disease had not been established. Therefore use in these circumstances was only recommended as part of ongoing or new clinical studies.
TA066	2003	MTA	Olanzapine	Bipolar disorder	Recommended	Guidance has been incorporated in CG38. Recommendation in line with marketing authorisation.
TA066	2003	MTA	Valproate semisodium	Bipolar disorder	Recommended	Guidance has been incorporated in CG38. Recommendation in line with marketing authorisation.
TA067	2003	MTA	Oseltamivir	Influenza (prevention)	Recommended	Guidance has been replaced by TA158. Recommendation in line with national influenza guidelines.
TA067	2003	MTA	Amantadine	Influenza (prevention)	Not recommended	Guidance has been replaced by TA158. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups.
TA068	2003	MTA	Photodynamic therapy (PDT)	Macular degeneration	Optimised	Optimised recommendation for use in specific circumstances for people with wet age-related macular degeneration who have a confirmed diagnosis of classic with no occult subfoveal CNV and best-corrected visual acuity 6/60 or better.
TA069	2003	MTA	Liquid Based Cytology (LBC)	Cervical cancer	Recommended	Update of guidance TA5. Moved to static list in 2007. Recommendation in line with clinical practice.
TA070	2003	MTA	Imatinib	Leukaemia (CML)	Recommended	Update of guidance TA50. Recommendation in line with marketing authorisation
TA071	2003	MTA	Drug-eluting stent	Ischaemic heart	Optimised	Update of guidance TA4. Optimised

			(DES) - paclitaxel-eluting	disease		recommendation for use under specific circumstances depending on vessel anatomy.
TA071	2003	MTA	Bare-metal stent (BMS)	Ischaemic heart disease	Recommended	Update of guidance TA4. Recommendation in line with clinical practice.
TA071	2003	MTA	Drug-eluting stent (DES) - sirolimus-eluting	Ischaemic heart disease	Optimised	Update of guidance TA4. Optimised recommendation for use under specific circumstances depending on vessel anatomy.
TA072	2003	MTA	Anakinra	Rheumatoid arthritis	Only in Research	Guidance has been incorporated in CG79. At the time of appraisal, there was insufficient evidence to recommend anakinra for the treatment of rheumatoid arthritis, except in the context of a controlled, long-term clinical study.
TA073	2003	MTA	Myocardial perfusion scintigraphy (MPS) using single photon emission computed tomography (SPECT)	Angina and myocardial infarction	Recommended	Guidance has been partially incorporated in CG95. Recommendation in line with clinical practice.
TA074	2004	MTA	Pre-hospital fluid replacement therapy - crystalloid solutions	Trauma	Recommended	Recommendation in line with clinical practice.
TA075	2004	MTA	Peginterferon alfa and ribavirin – combination therapy	Hepatitis C	Recommended	Update of guidance TA14. Recommendation in line with marketing authorisation.
TA075	2004	MTA	Peginterferon alfa monotherapy	Hepatitis C	Recommended	Update of guidance TA14. Recommendation in line with marketing authorisation.
TA076	2004	MTA	Gabapentin	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
TA076	2004	MTA	Lamotrigine	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
TA076	2004	MTA	Levetiracetam	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
TA076	2004	MTA	Oxcarbazepine	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
TA076	2004	MTA	Tiagabine	Epilepsy (adults)	Recommended	Recommendation in line with marketing

						authorisation.
TA076	2004	MTA	Topiramate	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
TA076	2004	MTA	Vigabatrin	Epilepsy (adults)	Recommended	Recommendation in line with marketing authorisation.
TA077	2004	MTA	Zaleplon	Insomnia	Recommended	Recommendation in line with marketing authorisation.
TA077	2004	MTA	Zolpidem	Insomnia	Recommended	Recommendation in line with marketing authorisation.
TA077	2004	MTA	Zopiclone	Insomnia	Recommended	Recommendation in line with marketing authorisation.
TA078	2004	MTA	Fluid-filled thermal balloon endometrial ablation	Menstrual bleeding	Recommended	Recommendation in line with clinical practice.
TA078	2004	MTA	Microwave endometrial ablation	Menstrual bleeding	Recommended	Recommendation in line with clinical practice.
TA079	2004	MTA	Gabapentin	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
TA079	2004	MTA	Lamotrigine	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
TA079	2004	MTA	Oxcarbazepine	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
TA079	2004	MTA	Tiagabine	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
TA079	2004	MTA	Topiramate	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
TA079	2004	MTA	Vigabatrin	Epilepsy (children)	Recommended	Recommendation in line with marketing authorisation.
TA080	2004	MTA	Clopidogrel	Acute coronary syndromes	Optimised	Guidance has been incorporated in CG94. Optimised recommendation for use in specific circumstances for people who are at moderate to high risk of myocardial infarction or death.
TA081	2004	MTA	Alclometasone dipropionate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.

TA081	2004	MTA	Beclometasone dipropionate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Betamethasone Esters (in guidance: Betamethasone valerate)	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Clobetasol propionate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Clobetasone butyrate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Desoximetasone (old name: desoxymethasone)	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Diflucortolone valerate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Fludrocortide	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Fluocinolone acetonide	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Fluocinonide	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Fluocortolone	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Fluticasone propionate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Halcinonide	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Hydrocortisone	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Hydrocortisone butyrate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA081	2004	MTA	Mometasone furoate	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA082	2004	MTA	Pimecrolimus	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.

TA082	2004	MTA	Tacrolimus	Atopic dermatitis (eczema)	Recommended	Recommendation in line with clinical practice.
TA083	2004	MTA	Laparoscopic surgery - totally extraperitoneal procedure [TEP]	Hernia	Recommended	Recommendation in line with clinical practice.
TA083	2004	MTA	Laparoscopic surgery - transabdominal preperitoneal procedure [TAPP]	Hernia	Recommended	Recommendation in line with clinical practice.
TA084	2004	MTA	Drotrecogin	Sepsis (severe)	Recommended	Recommendation in line with marketing authorisation.
TA085	2004	MTA	Induction therapy (basiliximab)	Renal transplantation (adults)	Recommended	Recommendation in line with marketing authorisation.
TA085	2004	MTA	Induction therapy (daclizumab)	Renal transplantation (adults)	Recommended	Recommendation in line with marketing authorisation.
TA085	2004	MTA	Mycophenolate mofetil (MMF)	Renal transplantation (adults)	Optimised	Optimised recommendation for use in specific circumstances for people with proven intolerance to calcineurin inhibitors, particularly nephrotoxicity leading to risk of chronic allograft dysfunction, or; in situations where there is a very high risk of nephrotoxicity necessitating minimisation or avoidance of a calcineurin inhibitor.
TA085	2004	MTA	Sirolimus	Renal transplantation (adults)	Optimised	Optimised recommendation for use in specific circumstances for people with proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitating complete withdrawal of these treatments.
TA085	2004	MTA	Tacrolimus	Renal transplantation (adults)	Recommended	Recommendation in line with marketing authorisation.
TA086	2004	MTA	Imatinib	Gastrointestinal stromal tumours	Recommended	Recommendation in line with marketing authorisation.
TA087	2005	MTA	Alendronate	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the

						need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor.
TA087	2005	MTA	Etidronate	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor.
TA087	2005	MTA	Raloxifene	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use under specific circumstances for women in whom bisphosphonates are contraindicated or who are physically unable to comply with the special recommendations for use of bisphosphonates, or who have had an unsatisfactory response to bisphosphonates, or who are intolerant of bisphosphonates.
TA087	2005	MTA	Risedronate	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in

						postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor.
TA087	2005	MTA	Teriparatide	Osteoporosis - secondary prevention	Optimised	Guidance has been replaced by TA161. Optimised recommendation for use under specific circumstances for women aged 65 years and older who have had an unsatisfactory response to bisphosphonates or intolerance to bisphosphonates, and who have an extremely low BMD (with a T-score of approximately -4 SD or below), or who have a very low BMD (with a T-score of approximately -3 SD or below) plus multiple fractures (that is, more than two) plus one, or more, additional age-independent risk factor: low body mass index (< 19 kg/m ²); family history of maternal hip fracture before the age of 75 years; untreated premature menopause; conditions associated with prolonged immobility.
TA088	2005	MTA	Dual chamber pacemakers	Bradycardia	Recommended	Recommendation in line with clinical practice.
TA089	2005	MTA	Autologous chondrocyte implantation (ACI)	Cartilage injury	Only in Research	Update of guidance TA16. At the time of appraisal, there was insufficient evidence on the effectiveness of ACI for it to be recommended, except in the context of new or ongoing clinical studies designed to generate robust and relevant outcome data including the measurement of health related quality of life and long term follow up.
TA090	2005	MTA	Modified-release (MR) dipyridamole	Vascular disease	Optimised	Optimised recommendation for use in specific circumstances in combination with aspirin for people who have had an ischaemic stroke or a transient ischaemic attack for a period of 2 years from the most recent event.
TA090	2005	MTA	clopidogrel	Vascular disease	Optimised	Optimised recommendation for use in specific circumstances for people who are intolerant of low-

						dose aspirin and either have experienced an occlusive vascular event or have symptomatic peripheral arterial disease.
TA091	2005	MTA	Pegylated liposomal doxorubicin hydrochloride (PLDH)	Ovarian cancer (advanced)	Recommended	Update of guidance TA45. Recommendation in line with marketing authorisation.
TA091	2005	MTA	Topotecan	Ovarian cancer (advanced)	Recommended	Update of guidance TA28. Recommendation in line with marketing authorisation.
TA091	2005	MTA	Paclitaxel	Ovarian cancer (advanced)	Recommended	Recommendation in line with marketing authorisation.
TA091	2005	MTA	Paclitaxel in combination with a platinum-based compound	Ovarian cancer (advanced)	Recommended	Recommendation in line with marketing authorisation.
TA092	2005	MTA	HealOzone	Tooth decay	Only in Research	At the time of appraisal, the Committee concluded that there was insufficient evidence on the effectiveness of HealOzone treatment for this technology to be recommended, except as part of well designed randomised controlled trials.
TA093	2005	MTA	Irinotecan	Colorectal cancer (advanced)	Recommended	Update of guidance TA33. Recommendation in line with marketing authorisation.
TA093	2005	MTA	Irinotecan in combination with 5-fluorouracil and folinic acid	Colorectal cancer (advanced)	Recommended	Update of guidance TA33. Recommendation in line with marketing authorisation.
TA093	2005	MTA	Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA)	Colorectal cancer (advanced)	Recommended	Update of guidance TA33. Recommendation in line with marketing authorisation.
TA093	2005	MTA	Raltitrexed	Colorectal cancer (advanced)	Only in Research	Update of guidance TA33. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only

						recommended for use in the context of appropriately designed clinical trials.
TA094	2006	MTA	Atorvastatin	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
TA094	2006	MTA	Fluvastatin	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
TA094	2006	MTA	Pravastatin	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
TA094	2006	MTA	Rosuvastatin	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
TA094	2006	MTA	Simvastatin	Cardiovascular disease	Recommended	Recommendation in line with clinical practice.
TA095	2006	MTA	Implantable cardioverter defibrillators (ICDs)	Arrhythmia (secondary prevention)	Recommended	Update of guidance TA11. Recommendation in line with clinical practice.
TA095	2006	MTA	Implantable cardioverter defibrillators (ICDs)	Arrhythmia (primary prevention)	Recommended	Update of guidance TA11. Recommendation in line with clinical practice.
TA096	2006	MTA	Adefovir dipivoxil	Hepatitis B (chronic)	Optimised	Optimised recommendation for use under specific circumstances if treatment with interferon alfa or peginterferon alfa-2a has been unsuccessful, or a relapse occurs after successful initial treatment, or treatment with interferon alfa or peginterferon alfa-2a is poorly tolerated or contraindicated.
TA096	2006	MTA	Adefovir dipivoxil in combination with lamivudine	Hepatitis B (chronic)	Optimised	Optimised recommendation for use under specific circumstances either alone or in combination with lamivudine when: treatment with lamivudine has resulted in viral resistance, or lamivudine resistance is likely to occur rapidly (for example, in the presence of highly replicative hepatitis B disease), and development of lamivudine resistance is likely to have an adverse outcome (for example, if a flare of the infection is likely to precipitate decompensated liver disease).

TA096	2006	MTA	Peginterferon alfa-2a	Hepatitis B (chronic)	Recommended	Recommendation in line with marketing authorisation.
TA097	2006	MTA	OCFighter (previously known as BTSteps) - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Not Recommended	Update of guidance TA51. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA097	2006	MTA	Beating the Blues - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Recommended	Update of guidance TA51. Recommendation in line with clinical practice.
TA097	2006	MTA	FearFighter - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Recommended	Update of guidance TA51. Recommendation in line with clinical practice.
TA097	2006	MTA	COPE - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Update of guidance TA51. At the time of appraisal there was insufficient evidence to recommend the technology as an option for the management of depression except as part of new or ongoing clinical trials designed to generate robust and relevant clinical effectiveness data.
TA097	2006	MTA	Overcoming Depression - computerised cognitive behavioural therapy (CCBT) package	Depression and anxiety	Only in Research	Update of guidance TA51. At the time of appraisal there was insufficient evidence to recommend the technology as an option for the management of depression except as part of new or ongoing clinical trials designed to generate robust and relevant clinical effectiveness data.
TA098	2006	MTA	Atomoxetine	Attention deficit hyperactivity disorder (ADHD)	Recommended	Update of guidance TA13. Recommendation in line with marketing authorisation.
TA098	2006	MTA	Dexamfetamine	Attention deficit hyperactivity disorder (ADHD)	Recommended	Update of guidance TA13. Recommendation in line with marketing authorisation.

TA098	2006	MTA	Methylphenidate	Attention deficit hyperactivity disorder (ADHD)	Recommended	Update of guidance TA13. Recommendation in line with marketing authorisation.
TA099	2006	MTA	Basiliximab	Renal transplantation - children and adolescents	Recommended	Recommendation in line with marketing authorisation.
TA099	2006	MTA	Daclizumab	Renal transplantation - children and adolescents	Recommended	Recommendation in line with marketing authorisation.
TA099	2006	MTA	Sirolimus	Renal transplantation (children)	Optimised	Optimised recommendation for use in specific circumstances for children or adolescents undergoing renal transplantation except proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitates the complete withdrawal of these treatments.
TA099	2006	MTA	Mycophenolate mofetil (MMF)	Renal transplantation (children)	Optimised	Optimised recommendation for use in specific circumstances when there is proven intolerance to calcineurin inhibitors, particularly nephrotoxicity which could lead to risk of chronic allograft dysfunction, or there is a very high risk of nephrotoxicity necessitating the minimisation or avoidance of a calcineurin inhibitor until the period of high risk has passed.
TA099	2006	MTA	Tacrolimus	Renal transplantation (children)	Recommended	Recommendation in line with marketing authorisation.
TA099	2006	MTA	Mycophenolate sodium (MPS)	Renal transplantation (children)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA100	2006	MTA	Capecitabine (adjuvant)	Colon cancer	Recommended	Recommendation in line with marketing authorisation. Moved to static list.
TA100	2006	MTA	Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (adjuvant)	Colon cancer	Recommended	Recommendation in line with marketing authorisation. Moved to static list.

TA101	2006	MTA	Docetaxel	Prostate cancer (hormone-refractory)	Recommended	Recommendation in line with marketing authorisation.
TA102	2006	MTA	Individual-based parent-training/education programmes	Conduct disorder in children	Recommended	Recommendation in line with clinical practice.
TA102	2006	MTA	Group-based parent-training/education programmes	Conduct disorder in children	Recommended	Recommendation in line with clinical practice.
TA103	2006	MTA	Efaluzimab	Psoriasis	Optimised	Optimised recommendation for use in specific circumstances in people with severe disease defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 after failure or intolerance to etanercept. Marketing authorisation was withdrawn by EMA after publication of TA103.
TA103	2006	MTA	Etanercept	Psoriasis	Recommended	Recommendation in line with clinical practice.
TA104	2006	MTA	Etanercept	Psoriatic arthritis	Recommended	Guidance has been replaced by TA199. Recommendation in line with clinical practice.
TA104	2006	MTA	Infliximab	Psoriatic arthritis	Optimised	Guidance has been replaced by TA199. Optimised recommendation for use in specific circumstances when a person has peripheral arthritis with three or more tender joints and three or more swollen joints; the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs (DMARDs), administered either individually or in combination; the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections.
TA105	2006	MTA	Laparoscopic resection	Colorectal cancer	Recommended	Update of guidance TA17. Recommendation in line with clinical practice.

TA106	2006	MTA	Peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin Combination therapy	Hepatitis C	Recommended	Recommendation in line with marketing authorisation.
TA106	2006	MTA	Peginterferon alfa-2a or peginterferon alfa-2b	Hepatitis C	Recommended	Recommendation in line with marketing authorisation.
TA107	2006	STA	Trastuzumab	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
TA108	2006	STA	Paclitaxel	Breast cancer (early)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA109	2006	STA	Docetaxel with doxorubicin and cyclophosphamide (the TAC regimen)	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
TA110	2006	STA	Rituximab	Follicular lymphoma	Recommended	Recommendation in line with marketing authorisation.
TA111	2006	MTA	Donepezil	Alzheimer's disease	Optimised	Update of guidance TA19. Optimised recommendation for use in specific circumstances for people with Alzheimer's disease with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
TA111	2006	MTA	Galantamine	Alzheimer's disease	Optimised	Update of guidance TA19. Optimised recommendation for use in specific circumstances for people with Alzheimer's disease with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
TA111	2006	MTA	Rivastigmine	Alzheimer's disease	Optimised	Update of guidance TA19. Optimised recommendation for use in specific circumstances, for people with Alzheimer's disease only with an MMSE score between 10 and 20 at the start of

						treatment. Treatment should only be continued while the patient has a score at or above 10.
TA111	2006	MTA	Memantine	Alzheimer's disease	Only in research	Update of guidance TA19. Only recommended in the context of well designed clinical trials.
TA112	2006	MTA	Anastrozole	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
TA112	2006	MTA	Exemestane	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
TA112	2006	MTA	Letrozole	Breast cancer (early)	Recommended	Recommendation in line with marketing authorisation.
TA113	2006	MTA	Inhaled insulin (Exubera)	Diabetes (type 1 and 2)	Optimised	Optimised recommendation for use in specific circumstances for people with type 1 or type 2 diabetes mellitus who show evidence of poor glycaemic control despite other therapeutic interventions (including, where appropriate, diet, oral hypoglycaemic agents [OHAs] and subcutaneous insulin) and adequate educational support, and who are unable to initiate or intensify pre-prandial subcutaneous insulin therapy because of either: a marked and persistent fear of injections that meet DSM-IV criteria for specific phobia 'blood injection injury type' diagnosed by a diabetes specialist or mental health professional; severe and persistent problems with injection sites (for example, as a consequence of lipohypertrophy) despite support with injection site rotation. Guidance now obsolete because manufacturer has ceased production of this technology.
TA114	2007	MTA	Buprenorphine (oral formulations)	Drug misuse	Recommended	Recommendation in line with clinical practice.
TA114	2007	MTA	Methadone (oral formulations)	Drug misuse	Recommended	Recommendation in line with clinical practice.
TA115	2007	MTA	Naltrexone	Drug misuse	Recommended	Recommendation in line with clinical practice.

TA116	2007	STA	Gemcitabine	Breast cancer	Recommended	Recommendation in line with marketing authorisation.
TA117	2007	MTA	Cinacalcet	Hyperparathyroidism (refractory)	Optimised	Optimised recommendation for use in specific circumstances for people with end-stage renal disease (including those with calciphylaxis) who have 'very uncontrolled' plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy; and a normal or high adjusted serum calcium level, and in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery are considered to outweigh the benefits.
TA118	2007	MTA	Bevacizumab in combination with 5-fluorouracil plus folinic acid (with or without irinotecan)	Colorectal cancer (metastatic)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA118	2007	MTA	Cetuximab in combination with irinotecan	Colorectal cancer (metastatic)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA119	2007	STA	Fludarabine (monotherapy)	Leukaemia (lymphocytic)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA120	2007	MTA	Cardiac resynchronisation therapy with a defibrillator device (CRT-D)	Heart failure	Recommended	Recommendation in line with clinical practice.
TA120	2007	MTA	Cardiac resynchronisation therapy with a pacing device (CRT-P)	Heart failure	Recommended	Recommendation in line with clinical practice.
TA121	2007	MTA	Carmustine implants	Glioma (newly diagnosed)	Recommended	Recommendation in line with clinical practice.

TA121	2007	MTA	Temozolomide	Glioma (newly diagnosed)	Recommended	Recommendation in line with clinical practice.
TA122	2007	STA	Alteplase	Ischaemic stroke (acute)	Recommended	Recommendation in line with marketing authorisation.
TA123	2007	STA	Varenicline	Smoking cessation	Recommended	Recommendation in line with marketing authorisation.
TA124	2007	STA	Pemetrexed (2nd line)	Non-small cell lung cancer	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA125	2007	STA	Adalimumab	Psoriatic arthritis	Recommended	Guidance has been replaced by TA199. Recommendation in line with clinical practice.
TA126	2007	STA	Rituximab	Rheumatoid arthritis (refractory)	Recommended	Guidance has been replaced by TA195. Recommendation in line with clinical practice.
TA127	2007	STA	Natalizumab	Multiple sclerosis	Recommended	Recommendation in line with marketing authorisation.
TA128	2007	MTA	Stapled haemorrhoidopexy	Haemorrhoid	Recommended	Recommendation in line with clinical practice.
TA129	2007	STA	Bortezomib	Multiple myeloma	Recommended	Recommended after agreement of Patient Access Scheme.
TA130	2007	MTA	Adalimumab (after DMARD failure)	Rheumatoid arthritis	Optimised	Optimised recommendation for use in specific circumstances for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated).
TA130	2007	MTA	Etanercept (after DMARD failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36. Optimised recommendation for use in specific circumstances, for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two

						occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated).
TA130	2007	MTA	Infliximab (after DMARD failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36. Optimised recommendation for use in specific circumstances for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated).
TA130	2007	MTA	Adalimumab (1st line)	Rheumatoid arthritis	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA130	2007	MTA	Etanercept (1st line)	Rheumatoid arthritis	Not Recommended	Update of guidance TA36. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA130	2007	MTA	Infliximab (1st line)	Rheumatoid arthritis	Not Recommended	Update of guidance TA36. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA131	2007	MTA	Inhaled corticosteroids (ICS) including beclometasone, budesonide, fluticasone, budesonide/formoterol combination, fluticasone/salmeterol combination	Asthma (in children)	Recommended	Recommendation in line with marketing authorisation.


TA132	2007	MTA	Ezetimibe (monotherapy)	Primary (heterozygous-familial and non-familial) hypercholesterolaemia	Recommended	Recommendation for in line with marketing authorisation.
TA132	2007	MTA	Ezetimibe (in combination with a statin)	Primary (heterozygous-familial and non-familial) hypercholesterolaemia	Recommended	Recommendation for in line with marketing authorisation.
TA133	2007	STA	Omalizumab	Severe persistent allergic (IgE mediated) asthma	Recommended	Recommendation in line with marketing authorisation.
TA134	2008	STA	Infliximab (2nd line)	Plaque psoriasis	Optimised	Optimised recommendation for use in specific circumstances when the psoriasis is very severe and has failed to respond to standard systemic therapies or the person is intolerant to or has a contraindication to these treatments. Treatment with infliximab should only be continued beyond 10 weeks if an adequate response to treatment is achieved.
TA135	2008	MTA	Pemetrexed disodium	Malignant pleural mesothelioma	Recommended	Recommendation in line with clinical practice.
TA136	2008	MTA	Structural neuroimaging techniques (either magnetic resonance imaging [MRI] or computed axial tomography [CT] scanning)	Psychosis (first episode)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.

TA137	2008	STA	Rituximab (3rd line)	Relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma	Recommended	Update of guidance TA37. Recommendation in line with marketing authorisation.
TA138	2008	MTA	Inhaled corticosteroids (ICS) including beclometasone, budesonide, fluticasone, budesonide/formoterol combination, fluticasone/salmeterol combination	Asthma (in adults)	Recommended	Recommendation in line with clinical practice.
TA139	2008	MTA	Fixed or autotitrating continuous positive airway pressure (CPAP) device	Obstructive sleep apnoea/hypopnoea syndrome (mild)	Recommended	Recommendation in line with clinical practice.
TA139	2008	MTA	Fixed or autotitrating continuous positive airway pressure (CPAP) device	Obstructive sleep apnoea/hypopnoea syndrome (moderate - severe)	Recommended	Recommendation in line with clinical practice.
TA140	2008	STA	Infliximab	Subacute, moderately to severely active ulcerative colitis	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA141	2008	STA	Abatacept	Rheumatoid arthritis	Not Recommended	Guidance has been replaced by TA195. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA142	2008	MTA	Erythropoietin analogues (epoetin alpha, epoetin beta, darbepoetin)	Cancer treatment-induced anaemia	Optimised	Optimised recommendation for use in specific circumstances for cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer who have symptomatic anaemia with a haemoglobin level of 8 g/100 ml or lower.

TA143	2008	MTA	Adalimumab	Severe ankylosing spondylitis (adults)	Recommended	Recommendation in line with clinical practice.
TA143	2008	MTA	Etanercept	Severe ankylosing spondylitis (adults)	Recommended	Recommendation in line with clinical practice.
TA143	2008	MTA	Infliximab	Severe ankylosing spondylitis (adults)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA144	2008	STA	Rimonabant	Overweight and obese adults	Optimised	Optimised recommendation for use in specific circumstances for adults who are obese or overweight and who have had an inadequate response to, are intolerant of, or are contraindicated to orlistat and sibutramine. EMA withdrew the marketing authorisation for this product after TA144 was published.
TA145	2008	STA	Cetuximab	Locally advanced squamous cell cancer of the head and neck	Optimised	Optimised recommendation for use in specific circumstances for people with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated.
TA146	2008	STA	Adalimumab	Plaque psoriasis	Recommended	Recommendation in line with clinical practice.
TA147	2008	STA	Bevacizumab (1st line)	Metastatic breast cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
TA148	2008	STA	Bevacizumab (1st line)	Unresectable advanced, metastatic or recurrent non-small-cell lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
TA149	2008	STA	Carmustine implants	Recurrent glioblastoma	Terminated Appraisal - non	The single technology appraisal process is based on the manufacturer's submission. In the absence

NICE technology appraisal decisions published since March 2000

36 of 50

 Shaded rows indicate guidance which has been subsequently updated.

				multiforme	submission	of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
TA150	2008	STA	Cetuximab (2nd-3rd line)	Metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
TA151	2008	MTA	Continuous subcutaneous insulin infusion (CSII or 'insulin pump') therapy	Type 1 diabetes mellitus	Optimised	Update of guidance TA57. Optimised recommendation for use in specific circumstances for people with type 1 diabetes whose HbA1c levels have remained high (at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care.
TA152	2008	MTA	Drug-eluting stents	Coronary artery disease	Optimised	Update of recommendations 1.2 – 1.4 in guidance TA71. Optimised recommendation for use in specific circumstances if a patient's target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15 mm.
TA153	2008	STA	Entecavir	Chronic Hepatitis B	Recommended	Recommendation in line with marketing authorisation.
TA154	2008	STA	Telbivudine	Chronic Hepatitis B	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA155	2008	MTA	Ranibizumab	Wet age-related macular degeneration	Recommended	Recommended after agreement of Patient Access Scheme.
TA155	2008	MTA	Pegaptanib	Wet age-related macular degeneration	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA156	2008	MTA	Routine antenatal anti-D prophylaxis	Pregnancy (rhesus negative women)	Recommended	Update of guidance TA41. Recommendation in line with marketing authorisation.
TA157	2008	STA	Dabigatran etexilate	Venous thromboembolism	Recommended	Recommendation in line with marketing authorisation.

				after hip or knee replacement surgery		
TA158	2008	MTA	Oseltamivir	Influenza (post-exposure prophylaxis)	Recommended	Update of guidance TA67. Recommendation in line with national influenza guidelines.
TA158	2008	MTA	Zanamivir	Influenza (post-exposure prophylaxis)	Recommended	Recommendation in line with national influenza guidelines.
TA158	2008	MTA	Amantadine	Influenza (post-exposure prophylaxis)	Not Recommended	Update of guidance TA67. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups.
TA159	2008	MTA	Spinal cord stimulation	Chronic pain of neuropathic origin	Optimised	Optimised recommendation for use in specific circumstances for adults who continue to experience chronic pain for at least 6 months despite appropriate conventional medical management.
TA159	2008	MTA	Spinal cord stimulation	Chronic pain of ischaemic origin	Only in Research	Only recommended in the context of research designed to generate robust evidence about the benefits of spinal cord stimulation (including pain relief, functional outcomes and quality of life) compared with standard of care.
TA160	2008	MTA	Alendronate	Fragility fractures in postmenopausal women with osteoporosis (primary prevention)	Optimised	Optimised recommendation for use under specific circumstances, for postmenopausal women aged 70 years or older who have an independent clinical risk factor for fracture or an indicator of low BMD and who are confirmed to have osteoporosis; In women aged 75 years or older who have two or more independent clinical risk factors for fracture or indicators of low BMD, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible; Women aged 65–69 years who have an independent clinical risk factor for fracture and who are confirmed to have osteoporosis; postmenopausal women

						younger than 65 years who have an independent clinical risk factor for fracture and at least one additional indicator of low BMD and who are confirmed to have osteoporosis (that is, a T-score of -2.5 SD or below).
TA160	2008	MTA	Etidronate	Fragility fractures in postmenopausal women with osteoporosis (primary prevention)	Optimised	Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible.
TA160	2008	MTA	Risedronate	Fragility fractures in postmenopausal women with osteoporosis (primary prevention)	Optimised	Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible.
TA160	2008	MTA	Raloxifene	Fragility fractures in postmenopausal	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS

				women with osteoporosis (primary prevention)		resources based on the data available.
TA160	2008	MTA	Strontium ranelate	Fragility fractures in postmenopausal women with osteoporosis (primary prevention)	Optimised	Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.
TA161	2008	MTA	Alendronate	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Recommended	Update of guidance TA87. Recommendation in line with marketing authorisation.
TA161	2008	MTA	Etidronate	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Update of guidance TA87. Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible.

TA161	2008	MTA	Risedronate	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Update of guidance TA87. Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible.
TA161	2008	MTA	Strontium ranelate	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.
TA161	2008	MTA	Raloxifene	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture.

TA161	2008	MTA	Teriparatide	Fragility fractures in postmenopausal women with osteoporosis (secondary prevention)	Optimised	Update of guidance TA87. Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to take alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate, or who have a contraindication to, or are intolerant of strontium ranelate, or who have had an unsatisfactory response to treatment with alendronate, risedronate or etidronate and who are 65 years or older and have a T-score of -4.0 SD or below, or a T-score of -3.5 SD or below plus more than two fractures, or who are aged 55–64 years and have a T-score of -4 SD or below plus more than two fractures.
TA162	2008	STA	Erlotinib	Non-small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation and following agreement of a Patient Access Scheme.
TA163	2008	STA	Infliximab	Acute, severely active ulcerative colitis	Recommended	Recommendation in line with marketing authorisation.
TA164	2008	STA	Febuxostat	Chronic hyperuricaemia (in people with gout)	Recommended	Recommendation in line with clinical practice.
TA165	2009	MTA	Machine perfusion systems (LifePort kidney transporter)	Organ preservation (renal)	Recommended	Recommendation in line with clinical practice.
TA165	2009	MTA	Cold Static Storage (Belzer UW storage solution or Marshall's hypertonic citrate solution)	Organ preservation (renal)	Recommended	Recommendation in line with clinical practice.

TA166	2009	MTA	Unilateral cochlear implantation	Severe to profound deafness in children and adults	Recommended	Recommendation in line with clinical practice.
TA166	2009	MTA	Simultaneous bilateral cochlear implantation	Severe to profound deafness in children and adults	Optimised	Optimised recommendation for use in specific circumstances for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; or children; or adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.
TA166	2009	MTA	Sequential bilateral cochlear implantation	Severe to profound deafness in children and adults	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA167	2009	MTA	Endovascular stent-grafts	Infra-renal abdominal aortic aneurysms (unruptured)	Recommended	Recommendation in line with clinical practice.
TA167	2009	MTA	Endovascular stent-grafts	Infra-renal abdominal aortic aneurysms (ruptured)	Only in Research	Only recommended for use in the context of research.
TA168	2009	MTA	Zanamivir	Influenza (treatment)	Recommended	Update of guidance TA58. Recommendation In line with national influenza guidelines.
TA168	2009	MTA	Oseltamivir	Influenza (treatment)	Recommended	Update of guidance TA58. Recommendation In line with national influenza guidelines.
TA168	2009	MTA	Amantadine	Influenza (treatment)	Not Recommended	Update of guidance TA58. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups.
TA169	2009	MTA	Sunitinib (1st line)	Advanced and/or metastatic renal cell carcinoma	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.

TA170	2009	STA	Rivaroxaban	Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention)	Recommended	Recommendation in line with marketing authorisation.
TA171	2009	STA	Lenalidomide	Multiple myeloma	Recommended	Recommended following agreement on Patient Access Scheme.
TA172	2009	STA	Cetuximab	Recurrent and/or metastatic squamous cell cancer of the head and neck	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA173	2009	STA	Tenofovir disoproxil fumarate	Chronic hepatitis B	Recommended	Recommendation in line with marketing authorisation.
TA174	2009	STA	Rituximab in combination with fludarabine and cyclophosphamide (1st line)	Chronic lymphocytic leukaemia	Optimised	Optimised recommendation for use in specific circumstances in combination with fludarabine and cyclophosphamide.
TA175	2009	STA	Gefitinib (2nd line)	Locally advanced or metastatic non-small-cell-lung cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
TA176	2009	STA	Cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX) (1st line)	Metastatic colorectal cancer	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.


TA176	2009	STA	Cetuximab in combination with 5-FU, folinic acid and irinotecan (FOLFIRI) (1st line)	Metastatic colorectal cancer	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
TA177	2009	STA	Alitretinoin	Severe chronic hand eczema	Recommended	Recommendation in line with clinical practice.
TA178	2009	MTA	Bevacizumab (1st line)	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA178	2009	MTA	Sorafenib (1st line)	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA178	2009	MTA	Temsirolimus (1st line)	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA178	2009	MTA	Sunitinib (2nd line)	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA178	2009	MTA	Sorafenib (2nd line)	Advanced and/or metastatic renal cell carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA179	2009	STA	Sunitinib	Unresectable and/or metastatic malignant gastrointestinal stromal tumours	Recommended	Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
TA180	2009	STA	Ustekinumab	Plaque psoriasis	Recommended	Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
TA181	2009	STA	Pemetrexed in combination with cisplatin (1st line)	Locally advanced or metastatic non-small-cell lung cancer	Recommended	Recommendation in line with clinical practice.

TA182	2009	STA	Prasugrel in combination with aspirin	Atherothrombotic events in people with acute coronary syndromes (prevention)	Recommended	Recommendation in line with clinical practice.
TA183	2009	STA	Topotecan in combination with cisplatin	Recurrent or stage IV cervical cancer	Recommended	Recommended in line with marketing authorisation.
TA184	2009	STA	Oral topotecan	Relapsed small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation.
TA184	2009	STA	Intravenous topotecan	Relapsed small-cell lung cancer	Not recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA185	2010	STA	Intravenous trabectedin	Advanced soft tissue sarcoma	Recommended	Recommended following agreement of Patient Access Scheme.
TA186	2010	STA	Certolizumab (subcutaneous injection)	Rheumatoid arthritis	Optimised	Optimised recommendation for use in specific circumstances in people who have not had an adequate response following the use of at least 2 DMARDs, and following agreement of Patient Access Scheme.
TA187	2010	MTA	Infliximab	Severe active Crohn's disease (adults)	Recommended	Update of guidance TA40. Recommendation in line with clinical practice.
TA187	2010	MTA	Adalimumab	Severe active Crohn's disease (adults)	Recommended	Recommendation in line with clinical practice.
TA187	2010	MTA	Infliximab	Active fistulising Crohn's disease (adults)	Recommended	Update of guidance TA40. Recommendation in line with clinical practice.
TA187	2010	MTA	Infliximab	Severe active Crohn's disease (6 - 17 years)	Recommended	Update of guidance TA40. Recommendation in line with clinical practice.

TA188	2010	MTA	Somatropin	Growth failure (children)	Recommended	Update of guidance TA42. Recommendation in line with clinical practice.
TA189	2010	STA	Sorafenib (1st line)	Advanced and metastatic hepatocellular carcinoma	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA190	2010	STA	Pemetrexed (maintenance treatment)	Non-small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation.
TA191	2010	STA	Capecitabine (1st line)	Inoperable advanced gastric cancer	Recommended	Recommendation in line with marketing authorisation
TA192	2010	STA	Gefitinib (1st line)	Locally advanced or metastatic non-small-cell lung cancer	Recommended	Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
TA193	2010	STA	Rituximab in combination with fludarabine and cyclophosphamide	Relapsed or refractory chronic lymphocytic leukaemia	Optimised	Optimised recommendation for use in specific circumstances for the treatment of people who have not previously received rituximab (or who have only received rituximab in the context of a clinical trial at a dose lower than the licensed dose for chronic lymphocytic leukaemia, or in combination with chemotherapy other than fludarabine and cyclophosphamide) and whose disease is not refractory to fludarabine.
TA193	2010	STA	Rituximab in combination with fludarabine and cyclophosphamide	Relapsed or refractory chronic lymphocytic leukaemia	Only in Research	For patients who have already received rituximab (in circumstances other than in the context of a clinical trial), rituximab in combination with fludarabine and cyclophosphamide should only be used in the context of research.
TA193	2010	STA	Rituximab in combination with chemotherapy (other than fludarabine and cyclophosphamide)	Relapsed or refractory chronic lymphocytic leukaemia	Only in Research	Due to a lack of clinical and cost effectiveness evidence, the Committee concluded that rituximab plus chemotherapy (other than fludarabine and cyclophosphamide) should only be used for the treatment of relapsed or refractory chronic lymphocytic leukaemia in the context of research.

NICE technology appraisal decisions published since March 2000

47 of 50

 Shaded rows indicate guidance which has been subsequently updated.

TA194	2010	STA	Denosumab	Therapy-induced bone loss in non-metastatic prostate cancer	Terminated Appraisal - non submission	The single technology appraisal process is based on the manufacturer's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
TA195	2010	MTA	Adalimumab in combination with methotrexate (after TNF failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
TA195	2010	MTA	Etanercept in combination with methotrexate (after TNF failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
TA195	2010	MTA	Infliximab in combination with methotrexate (after TNF failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.

TA195	2010	MTA	Rituximab in combination with methotrexate (after TNF failure)	Rheumatoid arthritis	Recommended	Update of guidance TA36, TA126 and TA141. Recommendation in line with clinical practice.
TA195	2010	MTA	Abatacept in combination with methotrexate (after TNF failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event.
TA195	2010	MTA	Adalimumab monotherapy (after TNF failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event.
TA195	2010	MTA	Etanercept monotherapy (after TNF failure)	Rheumatoid arthritis	Optimised	Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event.

TA196	2010	STA	Imatinib adjuvant	Gastrointestinal stromal tumours (resectable)	Not Recommended	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.
TA197	2010	STA	Dronedarone (2nd line)	Non-permanent atrial fibrillation	Optimised	Optimised recommendation for use under specific circumstances in people with atrial fibrillation not controlled by first line treatment who also have at least one cardiovascular risk factor.
TA198	2010	STA	Tocilizumab in combination with methotrexate	Rheumatoid arthritis	Optimised	Optimised recommendation for use under specific circumstances in people whose rheumatoid arthritis has responded inadequately to one or more tumour necrosis factor alpha (TNF-) inhibitors and whose rheumatoid arthritis has responded inadequately to rituximab or in whom rituximab is contraindicated or when rituximab is withdrawn because of an adverse effect.
TA199	2010	MTA	Etanercept	Psoriatic arthritis	Recommended	Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
TA199	2010	MTA	Infliximab	Psoriatic arthritis	Recommended	Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
TA199	2010	MTA	Adalimumab	Psoriatic arthritis	Recommended	Update of guidance TA104 and TA125. Recommendation in line with clinical practice.